https://mindmedicinelaw.com/briefing/psilocybin-for-suds-rct-review-highlights-efficacy-and-challenges-20260626-16933The Psychedelic Journalen2026-06-27T15:04:27.822422+00:00Psilocybin for SUDs: RCT Review Highlights Efficacy and Challengespsilocybin-assisted therapy, substance use disorders, randomized controlled trials, functional unblinding, psychedelic research, safety and efficacyhttps://mindmedicinelaw.com/briefing/louisiana-s-psychedelic-therapy-pilot-a-new-model-for-state-healthcare-20260626-16852The Psychedelic Journalen2026-06-26T22:03:31.854875+00:00Louisiana's Psychedelic Therapy Pilot: A New Model for State HealthcareLouisiana psychedelic therapy, opioid settlement funding, state healthcare innovation, psilocybin therapy, MDMA treatment, mental health reform, psychedelic pilot program, substance abuse treatment, healthcare policy, psychedelic researchhttps://mindmedicinelaw.com/briefing/chris-letheby-s-philosophy-of-psychedelics-an-ethical-framework-20260625-16936The Psychedelic Journalen2026-06-27T15:04:58.979960+00:00Chris Letheby's Philosophy of Psychedelics: An Ethical Frameworkphilosophy of psychedelics, Chris Letheby, ethical framework, psychedelic research, therapeutic psychedelics, psychedelic policy, consciousness studies, psychedelic ethics, Oxford University Press, psychedelic communityhttps://mindmedicinelaw.com/briefing/dopamine-signaling-in-mdd-ventral-striatum-perfusion-insights-20260625-16944The Psychedelic Journalen2026-06-27T15:04:49.009005+00:00Dopamine Signaling in MDD: Ventral Striatum Perfusion Insightsdopamine signaling, major depressive disorder, ventral striatum, cerebral blood flow, anhedonia, amisulpride, dopaminergic mechanisms, reward processing, clinical trials, neurosciencehttps://mindmedicinelaw.com/briefing/pharmacogenomics-in-anaesthesia-evidence-and-future-directions-20260625-16943The Psychedelic Journalen2026-06-27T15:04:39.236174+00:00Pharmacogenomics in Anaesthesia: Evidence and Future Directionspharmacogenomics, anaesthesia, analgesia, personalized medicine, genetic polymorphisms, clinical trials, drug metabolism, perioperative carehttps://mindmedicinelaw.com/briefing/psychedelics-for-resistant-depression-efficacy-and-safety-20260625-16670The Psychedelic Journalen2026-06-26T22:03:52.607513+00:00Psychedelics for Resistant Depression: Efficacy and Safetypsychedelics, resistant depression, clinical trials, neuroplasticity, mental health policy, adverse effects, evidence-based practices, psychiatry, therapeutic protocols, regulatory changeshttps://mindmedicinelaw.com/briefing/oral-s-ketamine-study-reveals-bioavailability-challenges-20260625-16678The Psychedelic Journalen2026-06-26T15:05:49.254825+00:00Oral S-ketamine Study Reveals Bioavailability Challengesoral S-ketamine, bioavailability, treatment-resistant depression, pharmacokinetics, pharmacodynamics, central nervous system effects, psychedelic research, S-ketamine study, depression treatment, clinical trialshttps://mindmedicinelaw.com/briefing/psychedelic-compound-s-potential-in-post-concussion-therapy-20260625-16425The Psychedelic Journalen2026-06-25T22:03:48.433543+00:00Psychedelic Compound's Potential in Post-Concussion Therapypsychedelic research, post-concussion treatment, neurology, mental health, clinical trials, serotonin receptors, brain injury, FDA regulations, psychedelic safety, therapeutic applicationshttps://mindmedicinelaw.com/briefing/exploring-very-low-dose-methylphenidate-in-behavioral-studies-20260624-16671The Psychedelic Journalen2026-06-26T22:04:02.145330+00:00Exploring Very-Low-Dose Methylphenidate in Behavioral Studiesvery-low-dose methylphenidate, functional activation, behavioral change, controlled testing, stimulant risks, cognitive enhancement, dose precision, pharmacological probe, ethical considerations, habit formationhttps://mindmedicinelaw.com/briefing/ketamine-assisted-psychotherapy-for-methamphetamine-insights-20260624-16634The Psychedelic Journalen2026-06-26T15:06:48.862373+00:00Ketamine-Assisted Psychotherapy for Methamphetamine: Insightsketamine-assisted psychotherapy, methamphetamine use disorder, qualitative study, psychological space, behavioral change, substance use treatmenthttps://mindmedicinelaw.com/briefing/ultrasonic-neuromodulation-impact-on-acc-for-pain-and-depression-20260624-16680The Psychedelic Journalen2026-06-26T15:06:30.661645+00:00Ultrasonic Neuromodulation: Impact on ACC for Pain and Depressionultrasonic neuromodulation, anterior cingulate cortex, chronic pain treatment, depression intervention, non-invasive brain modulation, neuropsychiatric disorders, focused ultrasound, cognitive-emotional modulationhttps://mindmedicinelaw.com/briefing/decoding-tspo-signals-in-neuroinflammation-new-probe-insights-20260624-16695The Psychedelic Journalen2026-06-26T15:06:21.876491+00:00Decoding TSPO Signals in Neuroinflammation: New Probe InsightsTSPO, neuroinflammation, fluorescent probe, microglia, CNS diseases, CSF1R inhibitor, disease-associated microgliahttps://mindmedicinelaw.com/briefing/dissociating-therapeutic-from-psychedelic-effects-new-insights-20260624-16635The Psychedelic Journalen2026-06-26T15:06:09.837992+00:00Dissociating Therapeutic from Psychedelic Effects: New Insightspsychedelic research, therapeutic effects, mental health treatment, serotonin 2A receptor, pharmacological strategies, psychedelic experiences, psychiatric conditions, psychopharmacology, clinical trials, neurosciencehttps://mindmedicinelaw.com/briefing/s-ketamine-trial-reveals-sustained-cns-effects-in-new-study-20260624-16672The Psychedelic Journalen2026-06-26T15:06:01.375894+00:00S-ketamine Trial Reveals Sustained CNS Effects in New Studys-ketamine, central nervous system effects, antidepressant research, pharmacodynamic biomarkers, transcranial magnetic stimulation, pharmaco-electroencephalography, clinical trials, neuroscience, biomarker strategies, psychedelic researchhttps://mindmedicinelaw.com/briefing/oral-ketamine-for-depression-current-debates-and-future-prospects-20260624-16344The Psychedelic Journalen2026-06-25T22:04:00.569398+00:00Oral Ketamine for Depression: Current Debates and Future Prospectsoral ketamine, treatment-resistant depression, antidepressant effects, NMDA receptor, clinical guidelines, safety and efficacy, mental health research, FDA, neuroplasticity, depression treatmenthttps://mindmedicinelaw.com/briefing/4-br-dmt-synthesis-evaluation-and-future-implications-20260623-16697The Psychedelic Journalen2026-06-26T22:03:42.351427+00:004-Br-DMT: Synthesis, Evaluation, and Future Implications4-Br-DMT, serotonergic activity, psychedelic research, tryptamine analogs, drug development, safety profile, structure–activity relationshipshttps://mindmedicinelaw.com/briefing/mbct-s-impact-on-brain-dynamics-in-depression-new-insights-20260623-16301The Psychedelic Journalen2026-06-25T22:04:10.220058+00:00MBCT's Impact on Brain Dynamics in Depression: New Insightsmindfulness-based cognitive therapy, major depressive disorder, brain dynamics, rumination, functional magnetic resonance imaging, treatment efficacy, biomarkers, hierarchical brain organization, clinical trials, mental health policyhttps://mindmedicinelaw.com/briefing/lc-ne-system-s-role-in-early-alzheimer-s-symptoms-20260622-16195The Psychedelic Journalen2026-06-26T22:04:21.600099+00:00LC-NE System's Role in Early Alzheimer's Symptomslocus coeruleus-norepinephrine system, early Alzheimer's symptoms, neuropsychiatric symptoms, biomarker-driven interventions, neuroimaging advances, clinical trials, public health, disease progression, therapeutic targets, neuromodulatory interventionshttps://mindmedicinelaw.com/briefing/hypnosis-and-meditation-in-mental-health-a-new-frontier-20260622-16169The Psychedelic Journalen2026-06-26T22:04:13.169261+00:00Hypnosis and Meditation in Mental Health: A New Frontier?hypnosis, meditation, mental disorders, non-pharmacological adjuncts, randomized controlled trials, cognitive behavioral therapy, neuroimaging, psychological resilience, standardized guidelines, integrative treatmenthttps://mindmedicinelaw.com/briefing/crp-levels-as-biomarkers-in-young-affective-disorder-patients-20260622-16170The Psychedelic Journalen2026-06-25T22:04:42.978528+00:00CRP Levels as Biomarkers in Young Affective Disorder PatientsC-reactive protein, suicidality biomarkers, major affective disorders, executive function, youth mental health, psychedelic researchhttps://mindmedicinelaw.com/briefing/psychedelics-and-aging-brains-new-research-initiative-launched-20260622-16424The Psychedelic Journalen2026-06-25T22:04:33.237961+00:00Psychedelics and Aging Brains: New Research Initiative Launchedpsychedelics, aging brains, cognitive decline, neuroplasticity, clinical trials, public health, regulatory challenges, psilocybin, LSD, mental healthhttps://mindmedicinelaw.com/briefing/psychedelic-therapies-for-trd-mechanisms-and-biomarkers-20260622-16321The Psychedelic Journalen2026-06-25T22:04:20.844429+00:00Psychedelic Therapies for TRD: Mechanisms and Biomarkerstreatment-resistant depression, psychedelic therapies, biomarkers, neuroinflammation, synaptic dysfunction, personalized medicine, rapid-acting antidepressants, neuromodulation, clinical trials, psychiatryhttps://mindmedicinelaw.com/briefing/synuclein-s-impact-on-pfc-in-parkinson-s-and-dementia-20260620-16137The Psychedelic Journalen2026-06-27T15:05:21.041770+00:00α-Synuclein's Impact on PFC in Parkinson's and Dementiaα-Synuclein, prefrontal cortex, Parkinson's Disease, Dementia with Lewy bodies, synaptic modulation, neuroprotective strategies, cognitive deficits, synaptic failure, glutamatergic synapses, GABAergic synapseshttps://mindmedicinelaw.com/briefing/neurodevelopmental-integrity-rethinking-substance-risk-20260620-16641The Psychedelic Journalen2026-06-27T15:05:11.663589+00:00Neurodevelopmental Integrity: Rethinking Substance Riskneurodevelopmental integrity, substance risk, developmental stages, public health, harm reduction, substance education, vulnerability, adolescents, young adults, policy implications